Some interesting statements in the announcement from Nov 2020 reading back through e.g "..The Company intends to translate this knowledge to its biochip development, and will continue exploring potential on-chip conversion of current diagnostics with the German Biotech teams.." "..Archer will work with its German Biotech partner to determine potential candidate biomolecules relevant to in-demand disease diagnostic tests, as part of the commercial development of Archer's A1 biochip.."
Sounds like the collaboration is continuing in the background..
Some interesting statements in the announcement from Nov 2020...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.61M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.0¢ | 22.5¢ | $63.00K | 276.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11728 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 58565 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| AXE (ASX) Chart |